This site use cookies
This site uses cookies that help us to improve our site by providing analytics and usage information. By clicking accept or continuing to use this site you are agreeing to our cookie policy. If you do not agree, please close this notice. Learn more

Professor Steven Harper



Steve has extensive expertise in medical applications of VEGF inhibitors, and jointly discovered anti-angiogenic VEGF165b.

His initial research training in molecular pathology took place in Leicester University on immune-mediated kidney disease. Since 1996, he has been a consultant nephrologist and transplant physician at the Richard Bright Renal Unit in Bristol, and jointly runs the Microvascular Research Laboratories in Bristol part-time.

His research interests revolve around how renal tissue phenotypes change in association with the mRNA repertoire, and how controlling these repertoire changes, that appear common to a particular paradigm (e.g. angiogenesis, hyper-permeability) may translate to clinical therapies in multiple disease states. He is the co-inventor of the patent on regulation of splicing and its therapeutic use, as well as on 6 other patents including that describing anti-angiogenic VEGF165b as a therapeutic.